Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN), Olema Pharmaceuticals (OLMA) and Hims & Hers Health (HIMS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biohaven Ltd. (BHVN – Research Report), Olema Pharmaceuticals (OLMA – Research Report) and Hims & Hers Health (HIMS – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biohaven Ltd. (BHVN)
In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Biohaven Ltd., with a price target of $14.00. The company’s shares closed last Wednesday at $11.54.
According to TipRanks.com, Semenkow is a 2-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Moderate Buy with an average price target of $17.33, a 52.2% upside from current levels. In a report issued on February 5, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
Olema Pharmaceuticals (OLMA)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Olema Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Wednesday at $22.41.
According to TipRanks.com, Nochomovitz is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Olema Pharmaceuticals with a $45.78 average price target, implying a 102.7% upside from current levels. In a report issued on February 4, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $29.00 price target.
Hims & Hers Health (HIMS)
In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Hims & Hers Health, with a price target of $40.00. The company’s shares closed last Wednesday at $15.84, close to its 52-week low of $11.20.
Hettenbach has an average return of
According to TipRanks.com, Hettenbach is ranked #4047 out of 12109 analysts.
Currently, the analyst consensus on Hims & Hers Health is a Hold with an average price target of $33.28, a 106.6% upside from current levels. In a report issued on February 5, Needham also maintained a Hold rating on the stock.
